Halozyme Therapeutics, Inc. (HALO)
108.18
-1.68
(-1.53%)
USD |
NASDAQ |
Oct 05, 11:49
Halozyme Therapeutics Profit Margin (Quarterly) : 47.80% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 47.80% |
| March 31, 2026 | 39.83% |
| December 31, 2025 | -31.34% |
| September 30, 2025 | 49.46% |
| June 30, 2025 | 50.71% |
| March 31, 2025 | 44.59% |
| December 31, 2024 | 45.98% |
| September 30, 2024 | 47.23% |
| June 30, 2024 | 40.30% |
| March 31, 2024 | 39.22% |
| December 31, 2023 | 37.12% |
| September 30, 2023 | 37.88% |
| June 30, 2023 | 33.82% |
| March 31, 2023 | 24.43% |
| December 31, 2022 | 31.79% |
| September 30, 2022 | 29.49% |
| June 30, 2022 | 14.89% |
| March 31, 2022 | 51.25% |
| December 31, 2021 | 65.46% |
| September 30, 2021 | |
| June 30, 2021 | 67.02% |
| March 31, 2021 | 31.34% |
| December 31, 2020 | 60.12% |
| September 30, 2020 | 55.43% |
| June 30, 2020 | 46.75% |
| Date | Value |
|---|---|
| March 31, 2020 | -24.07% |
| December 31, 2019 | -64.10% |
| September 30, 2019 | -54.11% |
| June 30, 2019 | -37.36% |
| March 31, 2019 | 3.15% |
| December 31, 2018 | -3.53% |
| September 30, 2018 | -109.0% |
| June 30, 2018 | -65.03% |
| March 31, 2018 | -88.95% |
| December 31, 2017 | 65.35% |
| September 30, 2017 | 4.31% |
| June 30, 2017 | -91.15% |
| March 31, 2017 | -111.3% |
| December 31, 2016 | -70.22% |
| September 30, 2016 | -90.87% |
| June 30, 2016 | -80.62% |
| March 31, 2016 | -46.63% |
| December 31, 2015 | 8.27% |
| September 30, 2015 | -117.7% |
| June 30, 2015 | 6.96% |
| March 31, 2015 | -80.94% |
| December 31, 2014 | -17.36% |
| September 30, 2014 | -138.8% |
| June 30, 2014 | -88.51% |
| March 31, 2014 | -221.9% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| AVITA Medical, Inc. | -35.31% |
| Iovance Biotherapeutics, Inc. | -47.64% |
| Incyte Corp. | 34.98% |
| BioCryst Pharmaceuticals, Inc. | 35.92% |
| Neurocrine Biosciences, Inc. | 15.06% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 165.6% |
| Return on Assets | 16.90% |
| Return on Invested Capital | 19.26% |
| Gross Profit Margin (Quarterly) | 77.40% |
| Operating Margin (Quarterly) | 59.80% |
| Return on Net Operating Assets | 21.91% |